Evidence map›Paper›PMID 24287722›Full record

ArticleCancer gene therapy2013

Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine.

C M Jay, C Ruoff, P Kumar, H Maass, B Spanhel, M Miller, A Arrington, N Montalvo, V Gresham, D D Rao and 12 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Pancreatic cancer actionable genes in precision medicine and personalized surgery.The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland · 2017
    Review
  3. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Article
  4. PDX1 associated therapy in translational medicine.Annals of translational medicine · 2016
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

C M JayGradalis, Dallas, TX, USA.
C RuoffTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
P KumarGradalis, Dallas, TX, USA.
H MaassTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
B SpanhelTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
M MillerTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
A ArringtonTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
N MontalvoTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
V GreshamTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
D D RaoGradalis, Dallas, TX, USA.
C EvansGradalis, Dallas, TX, USA.
Z WangGradalis, Dallas, TX, USA.
F C BrunicardiDepartment of Surgery, David Geffen School of Medicine at UCLA Medical Center, Los Angeles, CA, USA.
S-H LiuDepartment of Surgery, David Geffen School of Medicine at UCLA Medical Center, Los Angeles, CA, USA.
G ZhouDepartment of Surgery, David Geffen School of Medicine at UCLA Medical Center, Los Angeles, CA, USA.
N Senzer1] Gradalis, Dallas, TX, USA [2] Mary Crowley Cancer Research Centers, Dallas, TX, USA.
J Nemunaitis1] Gradalis, Dallas, TX, USA [2] Mary Crowley Cancer Research Centers, Dallas, TX, USA.
L KingTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
B WeeksTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
F J ClubbDepartment of Veterinary Pathobiology, Texas A&M University, College Station, TX, USA.
T W FossumTexas A&M Institute for Preclinical Studies, College Station, TX, USA.
P B MaplesGradalis, Dallas, TX, USA.
Gradalis (United States) · USOlive View-UCLA Medical Center · USMary Crowley Cancer Research Center · USTexas A&M University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PDX1 (pancreatic and duodenal homeobox 1) is overexpressed in pancreatic cancer, and its reduction results in tumor regression. Bi-functional pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) utilizes the endogenous micro-RNA biogenesis pathway to effect cleavage- and non-cleavage-dependent degradation of PDX1 mRNA. We have shown that OFHIRNA-PDX1 reduces pancreatic tumor volume in xenograft models. Thus, we are now exploring biorelevant large animal safety of OFHIRNA-PDX1. Mini pigs were chosen as the biorelevant species based on the similarity of human and pig PDX1 target sequence. In the initial study, animals developed fever, lethargy, hyporexia and cutaneous hyperemia following administration of OFHIRNA-PDX1. Twenty-one days later, the same animals demonstrated less toxicity with a second OFHIRNA-PDX1 infusion in conjunction with a prophylactic regimen involving dexamethasone, diphenhydramine, Indocin and ranitidine. In a new group of animals, PDX1 protein (31 kDa) expression in the pancreas was significantly repressed at 48 and 72 h (85%, P=0.018 and 88%, P=0.013; respectively) following a single infusion of OFHIRNA-PDX1 but recovered to normal state within 7 days. In conclusion, a single intravenous infusion of OFHIRNA-PDX1 in conjunction with premedication in pigs was well tolerated and demonstrated significant PDX1 knockdown.

Indexed as

NanoconjugatesAnimalsBase PairingBase SequenceBlood GlucoseBody TemperatureCell Line, TumorFemaleGene ExpressionGene OrderHomeodomain ProteinsHumansInsulinMicePlasmidsProtein IsoformsBlood GlucoseHomeodomain ProteinsInsulinNanoconjugatespancreatic and duodenal homeobox 1 proteinProtein IsoformsRNA, Small InterferingTrans-Activators

Identifiers

PMID24287722
OpenAlexW2078363702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.